
1023

RAW SEQUENCE LISTING ERROR REPORT BEST AVAILABLE COPY

of the torn



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/888,/82	
Source:	OIRE	_
Date Processed by STIC:	11/1/2001	_

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

OIPE

RAW SEQUENCE LISTING

DATE: 11/01/2001

PATENT APPLICATION: US/09/888,182

TIME: 14:15:17

Input Set : A:\ES.txt

Output Set: N:\CRF3\11012001\I888182.raw

Does Not Comply Corrected Diskette Needed

ERRORED SEQUENCES

-> 2 <210> SEQ ID NO: 1

3 <211> LENGTH: 27

4 <212> TYPE: DNA

5 <213> ORGANISM: Artificial Sequence

W--> 6 <220> FEATURE:

7 <223> OTHER INFORMATION: Description of Artificial Sequence: Erk5-specific

8 primer

W--> 0 <110> APPLICANT:

W--> 0 <120> TITLE INVENTION:

W--> 0 <160> NUMBER OF SEQ ID NOS:

W--> 9 <400> SEQUENCE: 1

E--> 10 cagccattcg atgtgggccc acgcta

26

Dle following pages

Please consult Sequera Rules

for wabit formet.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/888,182

DATE: 11/01/2001

TIME: 14:15:18

Input Set : A:\ES.txt

Output Set: N:\CRF3\11012001\1888182.raw

```
L:2 M:283 W: Missing Blank Line separator, <210> field identifier
L:6 M:283 W: Missing Blank Line separator, <220> field identifier
L:0 M:282 W: Numeric Field Identifier Missing, <110> is required.
L:0 M:282 W: Numeric Field Identifier Missing, <120> is required.
L:0 M:282 W: Numeric Field Identifier Missing, <160> is required.
L:9 M:283 W: Missing Blank Line separator, <400> field identifier
L:10 M:252 E: No. of Seq. differs, <211>LENGTH:Input:27 Found:26 SEQ:1
L:16 M:283 W: Missing Blank Line separator, <220> field identifier
L:19 M:283 W: Missing Blank Line separator, <400> field identifier
L:26 M:283 W: Missing Blank Line separator, <220> field identifier
L:30 M:283 W: Missing Blank Line separator, <400> field identifier
L:31 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:37 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:41 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:42 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:43 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:44 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:50 M:283 W: Missing Blank Line separator, <220> field identifier
L:54 M:283 W: Missing Blank Line separator, <220> field identifier
L:58 M:283 W: Missing Blank Line separator, <400> field identifier
L:59 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:60 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:61 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:62 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:65 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:78 M:283 W: Missing Blank Line separator, <220> field identifier
L:82 M:283 W: Missing Blank Line separator, <400> field identifier
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 L:88 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:99 M:283 W: Missing Blank Line separator, <220> field identifier
L:106 M:283 W: Missing Blank Line separator, <400> field identifier
L:107 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:109 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:110 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:112 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:113 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:0 M:203 E: No. of Seq. differs, <160> Number Of Sequences: Input (0) Counted (6)
```

These mandatory runeve identifies and response are missing

GEQUENCE LISTING

from the

legening of <210> 1 <211>(27)26 shown <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Erk5-specific primer <400> 1 26

cagccattcg atgtgggccc acgcta

Del ret poge for more enon

<210> 3
<211> 802
<212> DNA
<213> Mus musculus
<220>
<221> misc_feature
<222> (1)..(38)
<223> partial sequence of exon 2 from Erk5 gene
<400> 3
cgqnacctac tgtgccctat ggaggaattc agatctgtgt aagggagtgg gccaggagga 60
ggagacacag tcgggatcag cttagaagcc caggttcagt aatactgaag ttctggcagg 120
gcggttgaac ccagagtgat gcgggctgtg agtccaggac attggtaggg acagttctta 180

[Mathallum A. Aleg. 3]

Use of n and/or Xaa has been detected in the Sequence Listing.

Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

more n's are shown in seq. 3

sel samle Seguece Listing (attached)

```
Smith, John: Smithgene Inc.
            <110>
            <120>
                         Example of a Sequence Listing
(not mandator $130>
                         01-00001
                                                                                           ويبين
                         PCT/EP98/00001
            <140>
                         1998-12-31
            <1(1>
            <150>
                         US 08/999,999
            <151>
                         1997-10-15
            <160>
            <170>
                         PatentIn version 2.0
            <210>
                         389 .
            <211>
                         ANG
            <212>
                         Paramecium sp.
            <213>
           <220>
                         CDS
            <221>
            <222>
                        ·(279)...(389)
           <300>
           <301>
                         Doc. Richard
                         Isolation and Characterization of a Gene Encoding a
           <302>
                         Protease from Paramecium sp.
           <303>
                         Journal of Genes
           <304>
           <305>
           <306>
                         1 - 7
           <307>
                         1988-06-31
           <308>
                        123456
           <309>
                        1988-06-31
           <400>
                                                                                                   60
                                                                caccctgcta
                                                                             atcagatete
           agciglagic
                        attcctgtgt1
                                     cctcttctct
                                                   criggictics
                                                                                                  120
                                                   tgcagottca
                                                                caggcaggca
                                                                             ggcaggcagc
                        tcttgaccc.t;
                                     cctctgcctt
           agggagagtg
                                                                                                  180
                                                                             tgggttccgc
           tgatgtggca
                        attgctggca
                                     gtgccacagg
                                                   cttttcagcc
                                                                aggettaggg
                                                                                                  240
                                                                             cctctcgctc
           cgcggcgcgg
                        cggcccctct
                                     cgcgctcctc
                                                  tcgcgcctct
                                                                ctctcgctct
```

1

Appendix 3, page 2

ggacct		age	gtgag	cag	gagga	99999	ca	gttago	:	atg Met	gtt Val	tca Ser	atg Met	ttc Phe 5	agc Ser	296
	ct t	t c he	aaa Lys 10	tgg , Trp	cct Pro	.gga Gly	ttt Phe	tgt Cys 15	ttg Leu	ttt Phe	gtt Val	tgt Cys	t t g Leu 20	ttc Phe	caa Cln	344
	ro L	aa ys : 25	gtc -Val	ctc Leu	ccc Pro	tgt Cys	cac His	uca Ser	tca Ser		cag Gln	ccg Pro	, aat Asn₌		 .	389
<210><211>		2 37				•		:	<i>r</i> ~		4			i s c:	÷	
<212> <213>		PRT Par		ium s	o .					·		A				
<400> Het V 1	al Sc	2 r	Het	Phe 5	Sèr	Leu	Scr	Phe	Lys 10	Trp	Pro	Gly	Phq	Cys 15	Leu	
Phe V	al Cy	s	Leu 20	Phe	Cln	Cys	Pro	1.ys 25	Val	Leu	Pro	Cys	His 30	Ser	Ser	
Leu G	ln Pr 3	o , 5 _{1.7.}	Asn	Lgu	•								:	••		
<210><211><211><212><213>) 11 PRT Arti		al Se	quenc	c			÷					•		
<220> <223>	, .	Desi Link	igned er b	pept etwee	ide b n the	ased o	on si	ie and beta	pola chair	rity is of	to ac Prote	ιas in XY	a Z .			
<400> Mct Va 1		3 n 1	∙Gn	Glu S	Pro	Met	His	Thr	Glu 10	Ile						
<210><400>	4	1		,												

[Annex VIII follows]

E

table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other: Names and/or Initials	M v
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M when filed prior to assignment of appl. number
<140>	Current Applica- tion Numbér	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	М
<170>	Software	Name of software used to create the Sequence Listing	0
<210>	SEQ ID NO: #:	Response shall be an integer representing the SEQ ID NO shown	м
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

.<212>

Type

Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/ RNA molecule shall be further described in the <220> to <223> (cature section.

<213>

Organism.

Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.

<220>

Feature

;,4

Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.

M, under the following conditions: if "n,"
"Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGAN-ISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

М

<221>

Name/Key

Provide appropriate identifier for feature, pre-ferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6

M, under the following conditions:= if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence

<222>

Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

base was used in

a sequence

			a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if acid molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300> /	•
<301>	Authors	Preferably max of ten named authors of publi- cation; specify one name per line; preferable format: Surname, Other Names and/or Initials	0
<302>	Title		0
<303>	Journal		0
<304>	Volume		0
<305>	Issue		0
<306>	Pages		O ·
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	o :
<300>	Database Accession Number	Accession number assigned by data-base including database name	O
<309>	Database Entry Date:	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	0
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US	0

07/999,999

in feature

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	•
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd-	0
<313>	Relevant Residues	FROM (position) TO (position)	0
<400>	Sequence	follow the numeric identifier and should appear on the line pre-	M A A A A A A A A A A A A A A A A A A A

5. Section 1.024 is revised to read as follows:

- 1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable form required by 1.021(e) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media: outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.
- (6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;